Racura Oncology (ASX:RAC) Moat Score: 0/10 (As of Jun. 28, 2026)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.21
View Full Analysis

What is Racura Oncology Moat Score?

Racura Oncology has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Racura Oncology has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Racura Oncology might have No Moat - No discernible moat.


Racura Oncology  (ASX:RAC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Racura Oncology Moat Score Related Terms

ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price